Hybridyne Health is the multi-award-winning entity responsible for commercialization of more than a decade’s Research & Development by renowned US Govt. institution Brookhaven National Labs, in New York.

The company has already received FDA approval for ProxiScan for intra-operative and endo-cavity applications, and is currently pursuing clinical trials and next generation product development efforts in the USA and Canada.

Hybridyne Health has a growing suite of carefully curated Intellectual Property (IP) underpinning the competitive clinical and commercial advantages of miniaturizing a gamma camera for broad clinical use.

The companies initial focus is on developing critically-needed imaging and guidance tools for the woefully under-served Prostate Cancer market, and is in formal talks with 1 European and 1 US publicly-traded entity to combine imaging and intervention platforms to allow the deployment of this solution into every Urologist's office.


Our award-winning platform technology Proxiscan takes SPECT/CT, that typically requires a large room and $100,000s, and has miniaturized it to a hand-held device. This provides clinicians with the unique ability to place the detector directly adjacent to the site of disease, something that has not been done before.  Proxiscan is FDA approved. For more details on availability and pricing please contact Terry Lall at: tlall@hybridynehealth.com


Hybridyne Health's first clinically addressable market is for Prostate Cancer, where current imaging modalities have long proved sub-optimal, leading to under-diagnosis and over-treatment. Hybridyne will be formally launching the product, supported by new clinical data at the American Urology Association (AUA) in San Diego, May 2016. For more details and pricing on the The ProstaScan technology please contact Terry Lall at: tlall@hybridynehealth.com



B. L. Franc, S. Y. Cho, S. A. Rosenthal, Y. Cui, B. Tsui, K. M. Vandewalker, A. L. Holz, U. Poonanallee, M. G. Pomper, and R. B. James, “Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA) – Proof of concept and initial imaging results”, Eur. J. Radiol. 2013 Aug 12. Pii: S0720-048X(13)00395-1. Doi: 10.1016/j.ejrad.2013.07.025.

 Y. Cui, T. Lall, B. Tsui, J. Yu, G. Mahler, A. Bolotnikov, P. Vaska, G. De Geronimo, P. O’Connor, G. Mainken, J. Joyal, J. Barrett, G. Camarda, A. Hossain, K.-H. Kim, G. Yang, M. Pomper, S. Cho, K. Weisman, Y. Seo, J. Babich, N. LaFrance and R. B. James, Compact CdZnTe-Based Gamma Camera for Prostate Cancer Imaging”, Proc. SPIE 8191, International Symposium on Photoelectronic Detection and Imaging 2011: Advances in Imaging Detector and Applications, 819255 (September 08, 201). DOI: 10.1117/12.901078.

Yonggang Cui, Giuseppe S. Camarda, Anwar Hossain, Ge Yang, Utpal N. Roy, Terry Lall, and Ralph B. James, “Modeling an Interwoven Collimator for a 3D Endocavity Gamma Camera”, AIMS Medical Science, 3(1):103-114. DOI: 10.3934/medsci.2016.1.103.

M. Kamuda, Y. Cui, T. Lall, J. Ionson, G. S. Camarda, A. Hossain, G. Yang, U. N. Roy, and R. B. James, “Modeling of a slanted-hole collimator in a compact endo-cavity gamma camera”, Proceedings of SPIE - The International Society for Optical Engineering, v 8853, 2013, Medical Applications of Radiation Detectors III; DOI: 10.1117/12.2026854;  Article number: 88530L.